Nutex Health restates 2024 results: revenue $479.9M (+93.8% YoY), net income $52.1M vs loss $45.8M

Nutex Health Inc.

2025-Q3 EPS reported $8.87 revenue$723,578,000

Restated full-year 2024: revenue $479.9M (up 93.8% YoY); net income $52.1M vs net loss $45.8M in 2023.
Diluted EPS $9.69 vs diluted loss per share $10.39 in 2023; adjusted EBITDA $124.1M (up 1,046% YoY).
Restatement adjustments: non-cash reclassifications increased liabilities $13.4M, decreased equity similarly; net income lowered ~$0.5M.
Q4 2024 revenue $257.6M (+269.8% YoY); net income $61.6M vs net loss $31.6M in Q4 2023.
Company notes stock repurchase program and arbitration process as ongoing; cash balance $40.6M at Dec 31, 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.